Omnicare — Q3 2013 Earnings Presentation
17 slides from Omnicare's earnings presentation, Oct 23, 2013
Slide 1: Omnicare
Omnicare
Slide 2: Forward-Looking Statements
Forward-Looking Statements Certain of mace lovey it i the following re fe ‘d-lookir i i vate ities Litigation Reform Act of 1995. These forward-| Hooking statements include, but are not tte to, all statements ir ue intent, belief or Current regarding Such and involve k and orleaan risks, uncertainti
Slide 3: Table of Contents
Table of Contents Mhird-Quarter 2013 HIGHIQHUS ssi isssssscsescenesteassavesesessevesvestecineteteviaersee 4 _ Operating Metrics — Script Data | Operating Metrics — Long-Term Care Bed Data... Gross Profit & Adjusted Operating Income Adjusted Net Income & Cash EPS....... Adjusted Operating Income by
Slide 4: Third-Quarter 2013 Highlights
Third-Quarter 2013 Highlights Revenue of $1,581M; 5.3% year-over-year increase Gross profit of $370M; gross margin of 23.4% Adjusted EBITDA of $179M; 3.8% year-over-year increase Adjusted cash earnings per diluted share’) of $0.91; 5.8% higher than —— 3Q12 of $0.86 — 6.8M increase in share count dil
Slide 5: Operating Metrics: Script Data
Operating Metrics Script Data Prior Year Increase Increase / (In thousands, except %s) 3Q.2013 2@2013 (Decrease) _3Q2012 (Decrease) Long-Term Care Group Scripts: Generic scripts dis} 20,596 20,688 wo. 4%) 20,596 0.0% Branded scripts di 4,222 4,263, (1.0%) 4,085 3.4% ver-the-counter corps cepaneed 3,
Slide 6: Operating Metrics: Long-Term Care Bed Data
Operating Metrics Long-Term Care Bed Data Sequential Prior Year Increase / Increase / (In thousands) 3Q 2013 2Q2013 (Decrease) 3Q2012 (Decrease) Beds served: Beginning of period - LTC Beds 969 969 0 977 (8) Net change in beds served 2 1 3 (1) End of period - LTC Beds 971 969 2 980 (9) Patient relate
Slide 7: Gross Profit & Adjusted Operating Income
Gross Profit & Adjusted Operating Income()(2) Prior Year Increase / Increase / In a except per share data and %s_3Q 2013 2Q 2013 (Decrease) 3Q 2012 {Decrease} Net 581.0 $ 1,569.9 0.7% $ 1,501.3 5.3% Cost a sales 1,211.2 1,191.4 1.7% 1,130.1 72% Gross profit $ 378.5 (2.3%) $ 371.3 (0.4%) Rate 23.39%
Slide 8: Adjusted Net Income & Cash-based EPS
Adjusted Net Income & Cash- based EPS) Prior Year Increase / In millions, except per share data and %s 3Q 2013 pee 2013 Sasa) (Decrease) ‘Adjusted operating income 149.3 $ 149.4 = ery 7 3.9% faust inereat ‘expense, net of investment income (23.9) (23.4) g ey (24.9) (4.0%) Adjust e before income taxe
Slide 9: Adjusted Operating Income by Segment
Adjusted Operating Income by Segment “) ——_Sequential___ Prior Year Increase / Increase / 3Q2013_ 202013 (Decrease) _3Q 2012 (Decrease) In millions, except %s ong-Term Care Group Net sales $ 1,220.0 $1,2224 (0%) $ 1,218.3 0% Adjusted operating income”) 160.5 165.1 (3%) 162.7 (1%) Rate 13.15% 13.51%
Slide 10: Cash Flows
Cash Flows “) Sequential Prior Year Increase / Increase / In millions, except %s 3Q2013 202013 (Der serene) 3Q2012_ (Decrease) Net income $ (66.3) $ 522 (227.0%) $ 61.4 (208.0%) Adjustments to reconcile net income to net cash flows m operating activiti Depreciation expense 15.2 147 3.4% 13.8 10.1% A
Slide 11: Cash Deployment
Cash Deployment i Prior Year Increase / Increase / In millions, except %s 3Q.2013 202013 (Decrease) 3Q.2012_ (Decrease) Net cash flows from operating activities (reported) ~$ 192.0 $ 153.8 24.8" $ 196.3 (2.2%) Capital expenditures 27.3 23.7 15.2% 25.0 9.2% Acquisitions 35 0.3 1066.7% 338 (89.6%) Net
Slide 12: Full-Year 2013 Guidance
1. a a 4 is | Full-Year 2013 Guidance | Original Previous Current Guidance “) idance (2) Guidance ©) | | + Revenue $6.1B to $6.2B $6.1B to $6.3B $6.2B to $6.3B ; + Adjusted cash earnings | per diluted share) $3.47 to $3.57 $3.56 to $3.64 $3.60 to $3.62 2 Seraa $450M to $500M $475M to $525M $500M to
Slide 13: Appendix
RNY ly, “yg; Omnicare Appendix
Slide 14: Capital Structure
Capital Structure $1,800 0 2010 Major Debt Maturity Schedule” (in $ millions) ‘s of 9/30/10 mAs of 9/30/13 2015 2020 2025 2030 2035 2040 2045 Recent actions have reduced refi risk by sp jing out ities while also ing costs dts rt 088 0 2 7088 1
Slide 15: Working Capital Management
Working Capital Management Five Quarter Trend() Days of Inventory On Hand a 8 Day Sales Outstanding 8 ° 3a12 4q12 1013 1. _DOH= Ending Inventory (Quarry Cost of Sales /Daysin Quart) 1DS0 = Ending Account Receivable (Quarry Sles/Daysin Quai)
Slide 16: Selected Branded Drug Patent Expirations
Trlipix 4Q 2013 Aciphex Cymbalta Tobi Zemplar ib 2 Drugsatready launched shown in ray and tals FY 2014 Actonel Avelox Detrol LA Evista Exforge IR/HCT Hectorol Intuniv Lunesta Micardis IR/HCT Nexium Oxycontin Rapamune Renagel Renvela Xeloda FY 2015 Ability Aggrenox Avodart Gllevec Lovaza Namenda IR O
Slide 17: Omnicare
Omnicare